Current Report Filing (8-k)
July 24 2019 - 09:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): July 24,
2019
OWC Pharmaceutical Research Corp.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware |
|
98-0573566 |
(State
of Incorporation) |
|
(I.R.S.
Employer Identification No.) |
|
|
|
2 Ben Gurion Street, Ramat Gan, Israel |
|
4514760 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
Telephone Number, including area code: 972 (0)
3-758-2657
Not
Applicable
(Former
name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company [ ]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
8.01 Other Events.
OWC
Pharmaceuticals Research Corp. (“OWC”) announced that, on July 18,
2019, it received long-awaited approval from the Israeli Medical
Cannabis Agency to perform an efficacy study with OWC topical
ointment on psoriatic patients. Currently, the study is planned to
be conducted at the Kaplan Medical Center, an academic medical
center in Israel.
OWC
believes this is the first time that the Israeli Medical Cannabis
Agency has issued a permit for the treatment of psoriasis with a
cannabis-based product . The study will be divided into the
following two consecutive stages: (1) a pilot efficacy and dosage
study; and (2) based on the results of the first stage, a double
blind, placebo-controlled study.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC
PHARMACEUTICAL RESEARCH CORP. |
|
|
|
|
By:
|
/s/ Mordechai
Bignitz |
|
Name: |
Mordechai
Bignitz |
|
Title: |
Chief
Executive
Officer |
Dated:
July 24, 2019
OWC Pharmaceuticals Rese... (PK) (USOTC:OWCP)
Historical Stock Chart
From Dec 2020 to Jan 2021
OWC Pharmaceuticals Rese... (PK) (USOTC:OWCP)
Historical Stock Chart
From Jan 2020 to Jan 2021